Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989115 · ClinicalTrials.gov registry record · Phase 1
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
A Phase 1 study, sponsored by Revolution Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
NCT03989115 is a Phase 1 study that has completed, run by Revolution Medicines. The registered enrollment target is 113 participants.
The verdict
NCT03989115, a Phase 1 study, has completed, sponsored by Revolution Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D); and to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and osimertinib in adult participants with EGFR mutation-positive locally advanced or metastatic NSCLC.
Interventions
- DRUG Cobimetinib
- DRUG RMC-4630
- DRUG Drug: Osimertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03989115
The ClinicalTrials.gov registry entry for NCT03989115 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cobimetinib is the first listed.
NCT03989115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03989115 about?
NCT03989115 is a clinical study titled "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D); and...
What is the current status of trial NCT03989115?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2019-07-02. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT03989115?
The interventions under investigation include: Cobimetinib (DRUG), RMC-4630 (DRUG), Drug: Osimertinib (DRUG).
Who is sponsoring clinical trial NCT03989115?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.